

Contact:

Karen Kreeger

215-459-0544

Karen.kreeger@uphs.upenn.edu

Penn Researchers Present Phase II HIV Gene Therapy Trial Data at CROI 2010*Reduced Viral Load set points in subjects treated with Lexgenleucel-T (VRX496TM) following HAART interruption*

February 18, 2010 – Researchers from the **University of Pennsylvania School of Medicine** presented today the results from an ongoing Phase I/II open-label clinical trial of Lexgenleucel-T at the 16th Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, CA. Lexgenleucel-T is a cell and gene therapy product being investigated for the treatment of HIV infection. The current study examined the effect of Lexgenleucel-T infusions in HIV-1 infected individuals prior to being taken off their antiretroviral treatment (HAART) regimens as part of the study design's scheduled treatment interruption. In the study, seven of eight evaluable subjects experienced a decrease in viral load set point and one subject experienced prolonged, complete control of HIV viremia for more than 14 weeks in the absence of HAART. Viral load set point is the HIV RNA value specific for each infected individual in absence of anti-retroviral drug control. Higher viral load set point is correlated with more rapid disease progression to AIDS.

“We are excited to see these responses using autologous transfer of CD4+ T lymphocytes genetically modified with VRX496TM, a HIV-based lentiviral vector encoding for a RNA antisense targeting HIV *env*. These are subjects who were taken off of their antiretroviral treatment and are showing a better control of their infection as demonstrated by reduced viral load set points,” said **Pablo Tebas, M.D.**, director of the Adult AIDS Clinical Trials Unit, who presented the results at CROI. “Further study is needed to see whether these types of results will translate into a delay in disease progression.”

In the current study, several administrations of Lexgenleucel-T, each comprising approximately 10¹⁰ autologous CD4+ T cells transduced ex vivo with VRX496TM, were administered to 17 HIV-1 infected subjects who were fully suppressed on HAART. Each subject received three to six separate infusions over a period up to 13 weeks. Six weeks after the last infusion, eligible subjects underwent a scheduled treatment interruption to evaluate timing to HIV RNA recrudescence, changes in viral load set point and changes in CD4+ T cell count. Of the 17 subjects who received infusions, 13 (76%) underwent the scheduled treatment interruption. Eight of these 13 subjects (62%) were evaluable for the efficacy endpoint. Overall, 7 of 8 (88%) of the evaluable subjects had a decrease in viral load set point ranging from -0.26 to -0.98 Log₁₀. One subject maintained a complete control of HIV RNA viral load below the limit of detection (50 copies/ml) and a CD4+ cell count greater than 1200 cells/μL for over 14 weeks.

“It is notable that all patients on the protocol had elevated CD4+ counts after treatment with Lexgenleucel-T,” said **Carl June, M.D.**, professor of Pathology and Laboratory Medicine. “Achieving a complete control of HIV recrudescence following HAART interruption for over 14 weeks is, indeed, remarkable.”

Pablo Tebas, MD, David Stein, MD, Gwendolyn Binder, PhD, Larisa Zifchak, RN, Angelo Seda, RN, Jean Boyer, PhD, Faten Aberra, MD, Ronald Collman, MD, Gerard McGarrity, PhD, Bruce Levine, PhD and Carl June, MD, are all co-authors of this study. The study was funded by the NIH, NIAID. Drs. Tebas, Zifchak, Boyer, Aberra and Colman are affiliated with the Center for AIDS Research at the University of Pennsylvania, Philadelphia. Drs. Binder, Levine, June, and Boyer are affiliated with the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia. Drs. Stein and Seda are affiliated with the University of Pennsylvania School of Medicine, Philadelphia. Dr. McGarrity is an employee of VIRxSYS Corporation, Gaithersburg, Maryland. VIRxSYS is the owner of the Lexgenleucel-T therapy. No author on this study other than Dr. McGarrity is affiliated with VIRxSYS in any capacity beyond their roles as clinical collaborators on this project.

***Penn Medicine** is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the [University of Pennsylvania School of Medicine](#) (founded in 1765 as the nation's first medical school) and the [University of Pennsylvania Health System](#), which together form a \$3.6 billion enterprise.*

Penn's School of Medicine is currently ranked #3 in U.S. News & World Report's survey of research-oriented medical schools, and is consistently among the nation's top recipients of funding from the National Institutes of Health, with \$367.2 million awarded in the 2008 fiscal year.